DC
CRL icon

Davenport & Co’s Charles River Laboratories CRL Stock Holding History

Davenport & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,577
Closed -$237K – 1217
2025
Q1 		$237K Sell
1,577
-14,469
-90% -$2.43M ﹤0.01% 1084
2024
Q4 		$2.94M Sell
16,046
-701
-4% -$135K 0.02% 397
2024
Q3 		$3.32M Sell
16,747
-1,742
-9% -$362K 0.02% 359
2024
Q2 		$3.83M Buy
18,489
+5,582
+43% +$1.26M 0.02% 333
2024
Q1 		$3.48M Buy
12,907
+4,925
+62% +$1.18M 0.02% 350
2023
Q4 		$1.9M Buy
+7,982
New +$1.57M 0.01% 427
2022
Q3 		– Sell
-939
Closed -$201K – 998
2022
Q2 		$201K Buy
939
+85
+10% +$20.8K ﹤0.01% 917
2022
Q1 		$243K Sell
854
-112
-12% -$34.5K ﹤0.01% 943
2021
Q4 		$364K Sell
966
-530
-35% -$206K ﹤0.01% 844
2021
Q3 		$617K Buy
1,496
+793
+113% +$329K ﹤0.01% 669
2021
Q2 		$260K Buy
+703
New +$235K ﹤0.01% 839

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Davenport & Co's CRL Position: Q2 2025 in Review

Davenport & Co sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 1,577 shares — an estimated $237K sold.

Davenport & Co first reported a position in CRL in Q2 2021 and held it in 11 quarters. The position peaked at $3.83M in Q2 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Davenport & Co reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Davenport & Co sold 1,577 Charles River Laboratories shares in Q2 2025, an estimated $237K.
  • Davenport & Co first reported a position in Charles River Laboratories in Q2 2021 and held it in 11 quarters.
  • Davenport & Co's Charles River Laboratories position peaked at $3.83M in Q2 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Davenport & Co's 13F filing for Q2 2025, filed 22 Jul 2025.